Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | CBM588 + XL092 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| CBM588 | CBM 588|C. butyricum CBM 588 probiotic strain|MIYAIRI 588 | Microbiome 9 | CBM588 is a strain of Clostridium butyricum used as a probiotic, which induces the release of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), potentially resulting in increased tumor cell death and decreased tumor growth (PMID: 23354042). | |
| XL092 | XL-092|XL 092|Zanzalintinib | MET Inhibitor 59 VEGFR Inhibitor (Pan) 36 | XL092 is a receptor tyrosine kinase inhibitor that targets MET, AXL, VEGFR2, TYRO3, and MER, which potentially leads to decreased tumor cell proliferation and inhibition of tumor growth (PMID: 36399631). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07578025 | Phase II | CBM588 + XL092 | Zanzalintinib and MO-03 for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy | Not yet recruiting | USA | 0 |